In the Phase II trial in AML with bemcentinib in combination with low-dose cytarabine (LDAC), the pre-specified efficacy endpoint has been met; at least three patients out of the first 14 patients (21%) were required to achieve a clinical response.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Efficacy endpoint met in Phase II AML study 2 April 2019
- Published:
02 Apr 2019 -
Author:
Mick Cooper PhD -
Pages:
2
In the Phase II trial in AML with bemcentinib in combination with low-dose cytarabine (LDAC), the pre-specified efficacy endpoint has been met; at least three patients out of the first 14 patients (21%) were required to achieve a clinical response.